People: Talecris biotherapeutics holdings corp. (TLCR.O)

TLCR.O on Nasdaq

22.50USD
9 Feb 2010
Price Change (% chg)

$-0.05 (-0.22%)
Prev Close
$22.55
Open
$22.75
Day's High
$22.75
Day's Low
$22.21
Volume
97,019
Avg. Vol
268,952
52-wk High
$24.41
52-wk Low
$18.01

view people for:

Summary

Name Age Since Current Position
Stern, Lawrence 50 2007 Chairman of the Board, Chief Executive Officer
Hanson, John 55 2005 Chief Financial Officer, Executive Vice President
Gaither, John 58 2006 Executive Vice President, General Counsel, Secretary
Heerdt, Kari Senior Vice President - Human Resources
Engle, Jim 52 2005 Senior Vice President - Information Technology
Kuhn, Mary 48 2005 Senior Vice President - Operations
Lynch, Thomas 56 2006 Senior Vice President - Corporate Compliance, Regulatory & Public Policy
Petteway, Stephen 62 2005 Senior Vice President - Research & Development
Jones, Randall 50 2008 Senior Vice President - Special Projects
Nogales, Bruce 51 2007 Vice President, General Manager - International Commercial Operations
Perkins, John 36 Vice President, General Manager - U.S. Commercial Operations
Charpie, Richard 55 2005 Director
Ingersoll, W. Brett 45 2005 Director
Lenehan, James 60 2005 Director
Mayer, Steven 49 2005 Director
Waeger, Ruedi 65 2005 Director
Auerbach, Stuart 49 2005 Director
Mitchell, Dean 53 2009 Director
» Insider Trading

Biographies

Name Description
Stern, Lawrence Lawrence D. Stern has served as Chairman and Chief Executive Officer of Talecris Biotherapeutics Holdings Corp since June 2007, as a director since April 2005, and currently serves on the audit and finance committees. He was previously the Executive Chairman from April 2005 until June 2007. Mr. Stern worked with Cerberus and Ampersand in connection with the formation transaction. Prior to that, Mr. Stern served as the President of Bayer Corporation's Urethanes group upon Bayer's acquisition of Lyondell Chemical's polyol business. Mr. Stern received his BS in Chemical Engineering from Cornell University in 1979 and his MS from the Massachusetts Institute of Technology in 1981.
Hanson, John John M. Hanson has served as Executive Vice President and Chief Financial Officer of Talecris Biotherapeutics Holdings Corp since October 2005. From April 2003 until he joined in 2005, Mr. Hanson was employed at Andrx Corporation, a specialty pharmaceuticals company, where he ultimately served as Senior Vice President and Chief Financial Officer. From November 2000 to July 2001, Mr. Hanson served as Chief Financial Officer of Mylan Laboratories, a specialty pharmaceuticals company, and from September 1996 through October 2000, Mr. Hanson served as Chief Financial Officer of Zenith-Goldline Pharmaceuticals, Inc., the U.S. generic products subsidiary of IVAX Corporation. Mr. Hanson acted as controller of Barker Norton Pharmaceuticals from April 1995 to September 1996. Mr. Hanson was employed by Arthur Andersen LLP from 1984 to 1995 and is a certified public accountant. Mr. Hanson earned both his BS in Biology and his MPA from the University of South Dakota.
Gaither, John John F. Gaither, Jr. has been Executive Vice President, General Counsel and Secretary of Talecris Biotherapeutics Holdings Corp since September 2006. Prior to joining in 2006, Mr. Gaither served as Senior Vice President, General Counsel and Secretary of NeighborCare, Inc., one of the largest providers of institutional pharmacy services in the United States, from 2003 through 2005. Prior to that, from 2001 until 2003, Mr. Gaither served as Vice President, General Counsel and Secretary of Global Healthcare Exchange LLC, a company that provides an electronic trading exchange open to all health care providers, suppliers, and manufacturers that offers a forum to buy and sell a wide range of supplies and that also provides related services to improve the accuracy of pharmaceutical purchasing transactions. Mr. Gaither earned both his BBA in Accounting (in 1971) and his J.D. (in 1974) from the University of Notre Dame.
Heerdt, Kari As Senior Vice President of Human Resources, Kari Heerdt is responsible for managing Talecris’ Human Resources systems, programs and policies including employee recruitment, retention, compensation and benefits as well as organizational and leadership development. Ms. Heerdt is a seasoned Human Resources executive with more than 18 years of related management and consulting experience. Prior to joining Talecris, Ms. Heerdt served as Senior Vice President of Human Resources for Mervyns, a mid-market department store. She also served as a Senior Manager for Cerberus Capital Management, a leading investment management firm, and as a Senior Consultant for Hewitt Associates, a global Human Resources consulting and outsourcing services firm. Ms. Heerdt also held various Human Resources leadership positions within General Electric. Ms. Heerdt earned a Bachelor of Arts degree from Mount Holyoke College in South Hadley, Massachusetts and a Master of Science degree from the Krannert Graduate School of Management at Purdue University in West Lafayette, Indiana.
Engle, Jim Jim Engle has been Senior Vice President, Information Technology of Talecris Biotherapeutics Holdings Corp since April 2005. Prior to joining in 2005, Mr. Engle was with Aventis from 1988 to 2004. His most recent position at Aventis was Senior Vice President, IT for Aventis Behring (subsequently acquired by CSL Ltd. and renamed CSL Behring) from 1999 to 2004. Prior to Aventis, Mr. Engle was employed by Johnson & Johnson from 1982 to 1988. Mr. Engle attended Delaware Valley College of Science and Agriculture, where he earned his BS in Business Administration.
Kuhn, Mary Mary J. Kuhn has been Senior Vice President, Operations of Talecris Biotherapeutics Holdings Corp since April 2005. Prior to joining , Ms. Kuhn was a Senior Vice President of Operations at Bayer from October 2002 to April 2005. Prior to that, Ms. Kuhn was a Vice-President of Operations at Bayer. Ms. Kuhn earned her BS in Pharmacy from Purdue University and her EMBA from the University of New Haven.
Lynch, Thomas Thomas J. Lynch began as Vice President of Corporate Governance and Compliance of Talecris Biotherapeutics Holdings Corp in April 2005, and assumed his current position in early 2006. From 2003 to 2005, Dr. Lynch served as Vice President of Regulatory Affairs and Quality Assurance for CryoLife, Inc., a medical device and human tissue company. Prior to that, during 2000-2003, he served as Senior Vice President, Regulatory Affairs and Quality Assurance at Clearant, a biotechnology company engaged in pathogen inactivation R&D. From 1993 to 2000, Dr. Lynch had been with the U.S. Food and Drug Administration, most recently as Deputy Director of the Division of Hematology. Prior to joining the FDA, Dr. Lynch had spent about 15 years as a research scientist (protein chemistry and enzymology) in various capacities in the public, academic and private sectors. He holds a Ph.D. in biochemistry from Wayne State University and a law degree from Georgetown.
Petteway, Stephen Stephen R. Petteway, Jr., PhD, has served as Senior Vice President, Research & Development of Talecris Biotherapeutics Holdings Corp since April 2005. Prior to this, Dr. Petteway held various positions for Bayer Biological Products, including: Senior Director, Pathogen Safety & Research; Vice President, Pathogen Safety & Research; and Acting Head, Research & Technology. Prior to joining Bayer, he was Director of Drug Development for Cato Research Ltd.; Vice President and cofounder of Trimeris Inc.; and Director of Molecular Virology and Host Defense for SmithKleine Beecham Pharmaceuticals. His tenure with DuPont Co. was focused on the production of recombinant proteins and the development of diagnostics and blood screening tests. Dr. Petteway is the author of numerous scientific publications and patents related to diagnostics and therapeutics. Dr. Petteway earned his BA in Microbiology/Chemistry from the University of South Florida at Tampa in 1975, and his Ph.D. in Molecular Cell Biology from the University of Alabama at Birmingham in 1980.
Jones, Randall Randall A. Jones has served as Senior Vice President, Human Resources of Talecris Biotherapeutics Holdings Corp since June 2007 and Vice President, Human Resources since December 2006. He previously served as Vice President and General Counsel from April 2005 to September 2006. He has served as Assistant Secretary since May 2006. From April 2003 to March 2005, Mr. Jones was Vice President and Assistant General Counsel for the Biological Products Division of Bayer Healthcare LLC. From 1998 to 2003, Mr. Jones served in several roles, including General Counsel and Vice President, for Bayer CropScience, a company that manufactures and distributes crop protection and plant biotechnology products, and its predecessors Aventis CropScience and Rhone-Poulenc Ag Company. Mr. Jones earned his Bachelors in Chemical Engineering from the University of Delaware and his JD from the University of Virginia.
Nogales, Bruce Bruce Nogales joined Talecris Biotherapeutics Holdings Corp in 2005 as Vice President, International, responsible for the business transitions in Europe and Intercontinental Markets. He has also served as Vice President of both the Immunology and Pulmonary Commercial Development groups. In April 2007, Mr. Nogales was named Vice President and General Manager, International Commercial Operations. Prior to joining , Mr. Nogales had served from 1999 through 2004 at Aventis Behring (subsequently acquired by CSL Limited and renamed CSL Behring), which is engaged in the global protein therapeutics business, where he served as both Vice President & General Manager of Intercontinental Commercial Operations and of the Wound Healing Business Unit. He has also held key leadership positions at Genzyme Corporation and Allergan. Mr. Nogales earned his BS in Finance from California State University, Long Beach in 1978 and completed an Executive Development Program at the University of Pennsylvania's Wharton School of Business.
Perkins, John John R. Perkins joined Talecris Biotherapeutics in 2006 and currently serves as the Vice President & General Manager for the U.S. Commercial Operations. Prior to joining Talecris, John was a consultant to Cerberus Capital Management where he provided executive management since 2004 for several existing portfolio companies including Talecris and operational due diligence for potential investments. Mr. Perkins started his career with General Electric where he spent approximately ten years in a variety of positions including marketing/product management, sales, Corporate Audit, strategic planning and corporate business development (M&A). In addition to his experience at General Electric, he worked in Business Development for a start-up in Silicon Valley. Mr. Perkins is a graduate of General Electric's Management Development Program. He received his BA from DePauw University and earned his MBA from Northwestern's Kellogg School of Management.
Charpie, Richard Richard A. Charpie, PhD, has been a member of Talecris Biotherapeutics Holdings Corp board of directors since April 2005 and currently serves on the compensation committee and the compliance and quality committee. Dr. Charpie has been a managing general partner at Ampersand since its founding in 1988 as a spin-off from PaineWebber Incorporated. Dr. Charpie has served as a director of more than thirty-five public and private companies. Dr. Charpie earned both his BS and MS in Physics from the Massachusetts Institute of Technology. He also earned his PhD in Economics and Finance from the Massachusetts Institute of Technology.
Ingersoll, W. Brett W. Brett Ingersoll has been a member of Talecris Biotherapeutics Holdings Corp board of directors since April 2005 and currently serves on the compensation committee. Mr. Ingersoll has served as managing director of Cerberus Capital Management since 2003. From 1993 until 2002, Mr. Ingersoll served as a partner for J.P. Morgan Partners. In addition to serving on the board of the company, Mr. Ingersoll is also a member of the boards of directors of the following public companies: ACE Aviation Holdings (compensation and audit committees) and AerCap Holdings N.V. (nomination and compensation committee). Mr. Ingersoll received his BA in Economics from Brigham Young University and his MBA from Harvard Business School.
Lenehan, James James T. Lenehan has been a member of Talecris Biotherapeutics Holdings Corp board of directors since April 2005 and currently serves on the nominating committee and the compliance and quality committee. Since October 2004, Mr. Lenehan has also been a consultant for Cerberus Capital Management. Prior to that, Mr. Lenehan served in a variety of positions at Johnson & Johnson from October 1976 until he retired as Vice Chairman in June 2004. In addition, Mr. Lenehan is a member of the board of directors of Medtronic Inc. Mr. Lenehan earned his BA in Economics from the University of Akron and his MBA from Northwestern University.
Mayer, Steven Steven F. Mayer has been a member of Talecris Biotherapeutics Holdings Corp board of directors since April 2005 and currently serves on the audit and finance committees. Mr. Mayer has been managing director of Cerberus California, Inc. since November 2002. Prior to his work at Cerberus, Mr. Mayer acted as executive managing director of Gores Technology Group from December 2001 until November 2002. Mr. Mayer was also managing director of Libra Capital Partners from November 1996 until September 2001. From 1994 until 1996, Mr. Mayer was a managing director of Aries Capital Group, LLC, a private equity investment firm that he co-founded. From 1992 until 1994, Mr. Mayer was a principal with Apollo Advisors, L.P. and Lion Advisors, L.P., affiliated private investment firms. Prior to that time, Mr. Mayer was an attorney with Sullivan & Cromwell LLP. In addition to serving on the board of the company, Mr. Mayer is also a member of the board of directors of BlueLinx Holdings, Inc. Mr. Mayer received his AB, cum laude, from Princeton University and his JD, magna cum laude, from Harvard Law School.
Waeger, Ruedi Ruedi E. Waeger, PhD, has been a member of Talecris Biotherapeutics Holdings Corp board of directors since April 2005 and currently serves on the compensation committee and the compliance and quality committee. Dr. Waeger has over 30 years of experience in the global pharmaceutical and therapeutic protein industry. Most recently, Dr. Waeger served as President and Chief Executive Officer of Aventis Behring L.L.C., a global plasma therapeutics business which was acquired by CSL Ltd. in 2004 to form ZLB Behring. Prior to that, Dr. Waeger was President and Chief Executive Officer of ZLB Central Laboratories and Blood Transfusion Service of the Swiss Red Cross. Dr. Waeger also serves on the compensation committee of the board of directors at Alexion Pharmaceuticals, Inc., a manufacturer of pharmaceuticals for the treatment of autoimmune and cardiovascular diseases. Dr. Waeger earned a PhD in Biochemistry from the Swiss Federal Institute of Technology.
Auerbach, Stuart Stuart A. Auerbach has been a member of Talecris Biotherapeutics Holdings Corp board of directors since April 2005 and currently serves on the audit and finance committees. Mr. Auerbach has been a general partner with Ampersand since 1995, having previously served as an associate and partner dating back to 1991. During his tenure at Ampersand, Mr. Auerbach has served as a director of fifteen public and private companies. Mr. Auerbach earned his BS in Chemical Engineering from Columbia University and his MBA from Harvard Business School.
Mitchell, Dean Mr. Dean Jonathan Mitchell serves as Director of Talecris Biotherapeutics Holdings Corp. He most recently served as president and CEO at Alpharma Inc., a global specialty pharmaceutical company, and was also appointed to its board of directors. Alpharma was acquired by King Pharmaceuticals, Inc. in December 2008, and Mitchell ceased to be a director of Alpharma in December 2008. Prior to his tenure at Alpharma, Mitchell was president and CEO of Guilford Pharmaceuticals Inc. from December 2004 until its acquisition by MGI Pharma Inc. in October 2005. Mitchell was at Bristol-Myers Squibb from 2001 until 2004 in several roles, including president, international pharmaceuticals; president, U.S. primary care; and vice president, strategy. He also spent 15 years at GlaxoSmithKline and its predecessor companies, most recently as senior vice president, clinical development and product strategy, from 1999 to 2001, and prior to that as vice president and general manager of specialty divisions, strategic planning, and business development from 1995 to 1999. He received his MBA from City University Business School (London, UK) and his B.Sc. in biology from Coventry University, UK.

Insider Trading

Name Shares Traded Price
MENICHELLA DANIEL L 2,596 $19.75
AMP 99 MANAGEMENT COMPANY L L C 6,945,946 $19.00
FEINBERG STEPHEN 27,052,632 $17.96
GAITHER JOHN F JR 13,157 $0.00
NOGALES BRUCE 5,921 $0.00
LYNCH THOMAS J 2,631 $0.00
STERN LAWRENCE D 45,366 $0.00
PERKINS JOHN R II 5,921 $0.00
MENICHELLA DANIEL L 5,921 $0.00
HANSON JOHN MALCOLM 17,763 $0.00
ABELSON JOEL E 5,921 $0.00
KUHN MARY J 9,210 $0.00
PETTEWAY STEPHEN R JR 9,210 $0.00
ENGLE JAMES R 2,631 $0.00
HEERDT KARI D 3,947 $0.00
» Full list on Insider Trading
view people for: